Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por

Conjugate vs. Polysaccharide: The Science Behind Better Meningococcal Protection

Comprehensive comparison between meningococcal conjugate and polysaccharide vaccines, highlighting the immunological advantages of conjugate vaccines including long-duration antibody response, memory B cell production, and herd immunity benefits. Essential information for healthcare providers, immunization specialists, and public health officials seeking evidence-based vaccine selection guidance.

IMD in South Africa: Provincial Analysis and National Trends

Current analysis of Invasive Meningococcal Disease (IMD) trends in South Africa, featuring provincial statistics, seasonal patterns, and mortality rates. Highlights significant 53% increase in cases from 2022 to 2023, with special focus on Western Cape's higher incidence rates and nationwide surveillance data from GERMS-SA programme.

Risk Factors for Meningococcal Disease: Understanding Carriage and Transmission

Comprehensive overview of risk factors associated with meningococcal carriage and disease transmission, including crowded living conditions, intimate contact, passive smoking, and travel to hyperendemic areas. Essential information for healthcare providers and individuals in high-risk settings such as university dormitories, military barracks, and laboratory environments.

IMD Survivor Complications

Comprehensive analysis of Invasive Meningococcal Disease (IMD) complications, featuring statistical data from an 868-case Canadian study. Details both neurological and non-neurological complications, including hearing loss, motor deficits, and skin scarring, while exploring the emotional and economic burden on families and caregivers.

Part 1 of 10: What advantages does Toujeo (insulin glargine 300 U/mL) offer over older basal insulins

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

SULIQUA - Uproszczenie Schematu Leczenia Cukrzycy.

Zapraszamy do zapoznania się z materiałem prezentującym SULIQUA® - innowacyjne rozwiązanie w leczeniu cukrzycy typu 2. Dowiedz się, jak można uprościć schemat leczenia, poprawić kontrolę glikemii i zredukować ryzyko hipoglikemii przy jednym wstrzyknięciu dziennie. Materiał zawiera kluczowe informacje o skuteczności terapii i jej wpływie na jakość życia pacjentów.

Part 2 of 10: What outcomes have you observed in patients who have started Toujeo

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 3 of 10: What are the benefits of starting insulin naïve patients on a basal insulin instead of a premix or co-formulation insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 4 of 10: Managing post-prandial spikes – basal and premixed insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 5 of 10: The benefits of early combination therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 6 of 10: How does GLP-1 complement basal insulin in the management of type 2 diabetes

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 7 of 10: What to expect when using Toujeo (insulin glargine 300 U/mL) plus GLP-1 therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

«
‹
45
46
47
48
49
50
51
52
53
54
›
»

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

MAT-CO-2400825 V1.0 03/2024

Page menu

Actualización normativa

Conjugate vs. Polysaccharide: The Science Behind Better Meningococcal Protection

IMD in South Africa: Provincial Analysis and National Trends

Risk Factors for Meningococcal Disease: Understanding Carriage and Transmission

IMD Survivor Complications

Part 1 of 10: What advantages does Toujeo (insulin glargine 300 U/mL) offer over older basal insulins

SULIQUA - Uproszczenie Schematu Leczenia Cukrzycy.

Part 2 of 10: What outcomes have you observed in patients who have started Toujeo

Part 3 of 10: What are the benefits of starting insulin naïve patients on a basal insulin instead of a premix or co-formulation insulin

Part 4 of 10: Managing post-prandial spikes – basal and premixed insulin

Part 5 of 10: The benefits of early combination therapies

Part 6 of 10: How does GLP-1 complement basal insulin in the management of type 2 diabetes

Part 7 of 10: What to expect when using Toujeo (insulin glargine 300 U/mL) plus GLP-1 therapies